CN107849053B - 螺环化合物 - Google Patents

螺环化合物 Download PDF

Info

Publication number
CN107849053B
CN107849053B CN201680028591.0A CN201680028591A CN107849053B CN 107849053 B CN107849053 B CN 107849053B CN 201680028591 A CN201680028591 A CN 201680028591A CN 107849053 B CN107849053 B CN 107849053B
Authority
CN
China
Prior art keywords
optionally substituted
compound
unsubstituted
alkyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201680028591.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN107849053A (zh
Inventor
黄琴华
穆罕默德·卡赫拉曼
黛博·海伦·斯利
凯文·杜安·邦克
查德·丹尼尔·霍普金斯
约瑟夫·罗伯特·平奇曼
萨尼·亚伯拉罕
拉凯什·库马尔·西特
丹尼尔·李·塞弗伦斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zeno Yerti Milestone LLC
Original Assignee
Ricoram Ip Holding Co ltd
Kalyra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ricoram Ip Holding Co ltd, Kalyra Pharmaceuticals Inc filed Critical Ricoram Ip Holding Co ltd
Publication of CN107849053A publication Critical patent/CN107849053A/zh
Application granted granted Critical
Publication of CN107849053B publication Critical patent/CN107849053B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201680028591.0A 2015-04-03 2016-03-31 螺环化合物 Expired - Fee Related CN107849053B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562142946P 2015-04-03 2015-04-03
US62/142,946 2015-04-03
PCT/US2016/025345 WO2016161160A1 (en) 2015-04-03 2016-03-31 Spirocyclic compounds

Publications (2)

Publication Number Publication Date
CN107849053A CN107849053A (zh) 2018-03-27
CN107849053B true CN107849053B (zh) 2020-10-30

Family

ID=57007413

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680028591.0A Expired - Fee Related CN107849053B (zh) 2015-04-03 2016-03-31 螺环化合物

Country Status (25)

Country Link
US (3) US10525036B2 (enExample)
EP (1) EP3277690B1 (enExample)
JP (1) JP6737533B2 (enExample)
KR (1) KR20170132307A (enExample)
CN (1) CN107849053B (enExample)
AU (1) AU2016242940B2 (enExample)
BR (1) BR112017021194A2 (enExample)
CA (1) CA2981055A1 (enExample)
CY (1) CY1123019T1 (enExample)
DK (1) DK3277690T3 (enExample)
ES (1) ES2788160T3 (enExample)
HR (1) HRP20200805T1 (enExample)
HU (1) HUE049481T2 (enExample)
IL (1) IL254662B (enExample)
LT (1) LT3277690T (enExample)
MX (1) MX379622B (enExample)
PL (1) PL3277690T3 (enExample)
PT (1) PT3277690T (enExample)
RS (1) RS60340B1 (enExample)
RU (1) RU2745069C2 (enExample)
SG (1) SG11201707911VA (enExample)
SI (1) SI3277690T1 (enExample)
SM (1) SMT202000279T1 (enExample)
TW (1) TWI705067B (enExample)
WO (1) WO2016161160A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106999451B (zh) * 2014-09-17 2021-04-02 里科瑞尔姆Ip控股有限责任公司 双环化合物
EP3277690B1 (en) 2015-04-03 2020-02-26 Recurium IP Holdings, LLC Spirocyclic compounds
WO2018067512A1 (en) * 2016-10-05 2018-04-12 Kalyra Pharmaceuticals, Inc. Spirocyclic compounds
EA201991375A1 (ru) 2016-12-08 2020-01-20 Боард Оф Регентс, Зе Юниверсити Оф Тексас Систем Бицикло[1.1.1]пентановые ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания
US20210047324A1 (en) * 2018-01-31 2021-02-18 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2020215094A1 (en) 2019-04-18 2020-10-22 The Johns Hopkins University Substituted 2-amino-pyrazolyl-[1,2,4]triazolo[1,5a] pyridine derivatives and use thereof
US11560366B2 (en) 2019-10-21 2023-01-24 Board Of Regents, The University Of Texas System Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease
CN115124542A (zh) * 2022-07-08 2022-09-30 河南师范大学 羟基苯取代吡唑酮并吲唑[螺]吡唑酮类化合物的合成方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057579A1 (es) * 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
US8546404B2 (en) * 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
US7902363B2 (en) 2006-11-17 2011-03-08 Polyera Corporation Diimide-based semiconductor materials and methods of preparing and using the same
ES2556353T3 (es) 2008-02-21 2016-01-15 Merck Sharp & Dohme Corp. Compuestos que son inhibidores de las ERK
EP2318388A2 (en) 2008-07-23 2011-05-11 Schering Corporation Tricyclic spirocycle derivatives and methods of use thereof
AU2010300925A1 (en) 2009-09-30 2012-03-29 Merck Sharp & Dohme Corp. Novel compounds that are ERK inhibitors
EP2509636B1 (en) 2009-12-07 2017-07-19 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
US8664213B2 (en) 2011-08-29 2014-03-04 Bristol-Myers Squibb Company Spiro bicyclic diamine derivatives as HIV attachment inhibitors
CN103130775B (zh) * 2011-11-22 2015-09-30 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的吲哚满酮衍生物
US8987264B2 (en) * 2012-11-09 2015-03-24 Bristol-Myers Squibb Company 1,3,5-triazine derivatives of spiro bicyclic oxalamide-compounds for treatment of hepatitis C
AR095036A1 (es) 2013-03-14 2015-09-16 Kalyra Pharmaceuticals Inc Compuestos analgésicos bicíclicos
CN105732636B (zh) 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
EP3277690B1 (en) 2015-04-03 2020-02-26 Recurium IP Holdings, LLC Spirocyclic compounds
WO2018067512A1 (en) 2016-10-05 2018-04-12 Kalyra Pharmaceuticals, Inc. Spirocyclic compounds

Also Published As

Publication number Publication date
AU2016242940A1 (en) 2017-10-26
MX2017012553A (es) 2018-04-11
TWI705067B (zh) 2020-09-21
US10493060B2 (en) 2019-12-03
CY1123019T1 (el) 2021-10-29
WO2016161160A1 (en) 2016-10-06
RS60340B1 (sr) 2020-07-31
DK3277690T3 (da) 2020-05-04
EP3277690A1 (en) 2018-02-07
ES2788160T3 (es) 2020-10-20
IL254662A0 (en) 2017-11-30
TW201710261A (zh) 2017-03-16
HUE049481T2 (hu) 2020-09-28
HRP20200805T1 (hr) 2020-10-16
HK1256671A1 (en) 2019-09-27
RU2017133973A3 (enExample) 2019-07-17
RU2745069C2 (ru) 2021-03-18
CN107849053A (zh) 2018-03-27
CA2981055A1 (en) 2016-10-06
IL254662B (en) 2021-02-28
RU2017133973A (ru) 2019-05-06
KR20170132307A (ko) 2017-12-01
SI3277690T1 (sl) 2020-07-31
AU2016242940B2 (en) 2020-11-05
JP6737533B2 (ja) 2020-08-12
SG11201707911VA (en) 2017-10-30
EP3277690B1 (en) 2020-02-26
US10525036B2 (en) 2020-01-07
EP3277690A4 (en) 2018-08-22
LT3277690T (lt) 2020-06-10
US20180207132A1 (en) 2018-07-26
BR112017021194A2 (pt) 2019-01-08
PL3277690T3 (pl) 2020-08-24
PT3277690T (pt) 2020-03-24
SMT202000279T1 (it) 2020-07-08
US20200268714A1 (en) 2020-08-27
US20190201380A1 (en) 2019-07-04
JP2018511613A (ja) 2018-04-26
MX379622B (es) 2025-03-11

Similar Documents

Publication Publication Date Title
CN107849053B (zh) 螺环化合物
TWI794297B (zh) 化合物用於製備與第二抗-呼吸道融合性病毒試劑組合使用以治療呼吸道細胞融合病毒感染的藥物之用途及醫藥組合物
JP6949952B2 (ja) スピロ環化合物
WO2023217232A1 (zh) 驱动蛋白kif18a抑制剂及其应用
CN118922423A (zh) Ras抑制剂
KR20240026526A (ko) Ras를 억제하는 방법
CN107108561A (zh) 用作irak抑制剂的杂芳基化合物及其用途
KR20170040300A (ko) 2-(모르폴린-4-일)-l,7-나프티리딘
BR112017020900B1 (pt) Compostos de 1-ciano-pirrolidina como inibidores de usp30 e seu uso, composição farmacêutica
JP2023509155A (ja) ビフェニル系誘導体阻害剤、その調製方法及び使用
CA3078942A1 (en) Pyrrolotriazine compounds and methods of inhibiting tam kinases
ES3015269T3 (en) Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer
CN112313220B (zh) Pd-l1拮抗剂化合物
HK1256671B (en) Spirocyclic compounds
HK1242303B (zh) 用作irak抑制剂的杂芳基化合物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20181211

Address after: California, USA

Applicant after: Zeno Yerti Milestone LLC

Address before: California, USA

Applicant before: KALYRA PHARMACEUTICALS, Inc.

TA01 Transfer of patent application right
CB02 Change of applicant information

Address after: California, USA

Applicant after: Ricoram IP Holding Co.,Ltd.

Address before: California, USA

Applicant before: Zeno Yerti Milestone LLC

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20201030

CF01 Termination of patent right due to non-payment of annual fee